Bezafibrate Improves GLOBE and UK‐PBC Scores and Long‐Term Outcomes in Patients With Primary Biliary CholangitisAkira Honda, Atsushi Tanaka, Tetsuji Kaneko et al.|Hepatology|2019Cited by 119
Objective Response by mRECIST to Initial Lenvatinib Therapy Is an Independent Factor Contributing to Deep Response in Hepatocellular Carcinoma Treated with Lenvatinib-Transcatheter Arterial Chemoembolization Sequential TherapyHidekatsu Kuroda, Yasuhiro Takikawa, Takayoshi Oikawa et al.|Liver Cancer|2022Cited by 45
Environmental factors, medical and family history, and comorbidities associated with primary biliary cholangitis in Japan: a multicenter case–control studyKosuke Matsumoto, Atsushi Tanaka, Satoko Ohfuji et al.|Journal of Gastroenterology|2021Cited by 34
A validation study of the Ursodeoxycholic Acid Response Score in Japanese patients with primary biliary cholangitisMinami Yagi, Kosuke Matsumoto, Atsumasa Komori et al.|Liver International|2020Cited by 21
Influence of skeletal muscle volume loss during lenvatinib treatment on prognosis in unresectable hepatocellular carcinoma: a multicenter study in Tohoku, JapanMasashi Fujita, Hiromasa Ohira, Kazumichi Abe et al.|Scientific Reports|2022Cited by 17